ANGLE plc, a leading liquid biopsy company specializing in circulating tumor cell (CTC) diagnostics, will publish its financial results for the first half of 2025 on September 9th. The company announced the release date in a recent press release.
The company’s interim results will cover the period ending June 30, 2025. ANGLE will host an analyst meeting to discuss the results.
This meeting, originally planned as an in-person event, will be held virtually due to anticipated transportation disruptions in London. The change was made in response to planned tube strikes.
The virtual analyst meeting will be webcast live. A recording will be available later on the ANGLE investor relations website. Participation in the live question-and-answer session will be limited to analysts. Those wishing to participate should register in advance.
ANGLE‘s technology, the Parsortix® PC1 System, is FDA-cleared and patent-protected. It facilitates complete downstream analysis of blood samples, enabling comprehensive examination of CTCs. This includes whole cell imaging, proteomic analysis, and genomic and transcriptomic molecular analysis.
The company’s commercial activities are divided into clinical services and diagnostic product sales. The clinical services arm, operating through ANGLE‘s Good Clinical Laboratory Practice (GCLP)-compliant laboratories, offers customized assay development and clinical trial testing to pharmaceutical companies. The company also sells the Parsortix system itself, along with related consumables and assays.
The efficacy of the Parsortix system has been extensively documented in over 100 peer-reviewed publications.
Andrew Newland, Chief Executive Officer, and Ian Griffiths, Finance Director, will be available to answer questions at the virtual meeting. Berenberg is acting as the company’s NOMAD and corporate broker. FTI Consulting is handling media relations.
Related
